Biocon Limited (BOM:532523)

Market Cap	517.44B
Revenue (ttm)	164.76B
Net Income (ttm)	4.86B
Shares Out	n/a
EPS (ttm)	3.91
PE Ratio	106.58
Forward PE	50.20
Dividend	0.50 (0.13%)
Ex-Dividend Date	Jul 4, 2025

Volume	76,764
Average Volume	159,718
Open	391.60
Previous Close	390.40
Day's Range	388.20 - 394.90
52-Week Range	290.80 - 424.95
Beta	n/a
RSI	46.68
Earnings Date	Feb 12, 2026

About Biocon

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 16,315
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532523

Financial Performance

In 2024, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.